Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Pulmonary Drugs Market Forecast: Value Set To Climb From $60.06 Billion To $74.13 Billion
The pulmonary drugs market has demonstrated significant growth over recent years. It is forecast to expand from $56.98 billion in 2025 to $60.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.4%. This historical expansion can be attributed to various factors including a rise in asthma prevalence, increased incidence of COPD, escalating urban air pollution, the broader implementation of inhalation drug delivery, and improved methods for diagnosing respiratory diseases.
The pulmonary drugs market is anticipated to experience robust expansion over the coming years. By 2030, its valuation is projected to reach $74.14 billion, demonstrating a compound annual growth rate (CAGR) of 5.4%. This projected increase during the forecast period stems from factors such as an expanding aging demographic, the broader availability of biologic pulmonary medications, the integration of precision respiratory medicine, a rise in conditions linked to smoking, and better access to inhaled treatments. Key developments expected within this period involve the increasing uptake of targeted respiratory solutions, the proliferation of combination inhalation treatments, an enhanced emphasis on managing diseases over the long term, the expansion of biologic-derived pulmonary pharmaceuticals, and a move towards individualized respiratory care.
Get A Free Sample Report With In-Depth Market Insights:
Pulmonary Drugs Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The expanding occurrence of respiratory ailments is anticipated to fuel the expansion of the pulmonary drugs market moving ahead. These disorders are defined as health conditions impacting the lungs and airways, hindering typical respiration and oxygen transfer. The rise in respiratory disorders is attributed to the increasing incidence of smoking, which causes lung damage and persistent illnesses. Pulmonary drugs are vital in handling respiratory disorders, as they enhance lung function, decrease inflammation, and alleviate airway blockages to facilitate easier breathing. To illustrate, in May 2025, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, the age-adjusted COPD prevalence among adults 18+ stood at 3.8%, with women exhibiting higher rates (4.1%) compared to men (3.4%). The prevalence of COPD showed a sharp increase with age, climbing from 0.4% in adults 18–24 to 10.5% in those 75 and older. Consequently, the escalation of respiratory diseases is stimulating the expansion of the pulmonary drugs market.
Pulmonary Drugs Market Segment Outlook: Which Categories Are Growing Fastest?
The pulmonary drugs market covered in this report is segmented –
1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies
Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol
3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes
Pulmonary Drugs Market Innovation Trends Shaping Future Development
Leading firms within the pulmonary drugs market are concentrating on innovative therapeutic approaches, specifically dual PDE3 and PDE4 inhibition administered by inhalation. This aims to merge bronchodilator and non-steroidal anti-inflammatory properties into one molecule for managing chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition facilitates concurrent airway relaxation and a decrease in lung inflammation, tackling persistent COPD symptoms more efficiently than conventional treatments and streamlining administration by eliminating the need for intricate inhalation methods. As an example, in June 2024, Verona Pharma plc, a biopharmaceutical company from the UK, secured U.S. FDA approval for Ohtuvayre (ensifentrine). This product marks the initial inhaled therapy featuring such a dual-mechanism profile to be approved in more than 20 years. Administered through a standard jet nebulizer, Ohtuvayre offers both bronchodilator and anti-inflammatory advantages in a single dose. Its clinical effectiveness was demonstrated in the Phase 3 ENHANCE trials, both when used alone and alongside other maintenance treatments. The therapy is anticipated to be accessible via specialty pharmacies in the U.S. by the third quarter of 2024.
Pulmonary Drugs Market Leading Companies And Competitive Benchmarking
Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.
View The Full Pulmonary Drugs Market Report:
Pulmonary Drugs Market Largest Region By Revenue And Market Share
North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model